Kaplan Fox Files Class Action Against Unicycive Therapeutics

Kaplan Fox & Kilsheimer LLP has announced the filing of a class action lawsuit against Unicycive Therapeutics, Inc. (UNCY), a company listed on NASDAQ. The lawsuit, on behalf of investors who purchased or otherwise acquired Unicycive securities between December 29, 2025, and June 29, 2026, alleges that the company made false and misleading statements during this period.

According to the complaint, on June 30, 2026, before the market opened, Unicycive disclosed that the FDA had issued a Complete Response Letter (CRL) regarding the Company's resubmitted New Drug Application for its kidney disease therapy, oxylanthanum carbonate or OLC. This news caused Unicycive's stock price to fall $3.01, or 39.1%, to close at $4.69 per share on June 30, 2026, on unusually heavy trading volume.

The complaint further alleges that throughout the Class Period, Unicycive's management failed to disclose that the company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices. As a result, the company lacked a reasonable basis to believe that the vendor had resolved the FDA's cited deficiencies. The lawsuit also claims that there was an undisclosed risk that the FDA would require additional information about the vendor's facility's manufacturing practices.

Kaplan Fox & Kilsheimer LLP, a nationally recognized law firm with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey, is leading the lawsuit. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented. Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America, the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act, $800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.

If you are an investor in Unicycive and have suffered losses, you may contact Kaplan Fox & Kilsheimer LLP by emailing [email protected] or by calling (646) 315-9003. The deadline to move the court no later than November 2, 2026, to serve as a lead plaintiff for the purported class is approaching. If you have losses, the firm encourages you to contact them to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.

Source: Kaplan Fox & Kilsheimer LLP.